Progenics, Ono Pharmaceutical To Initiate RELISTOR Clinical Trials

Progenics and Ono Pharmaceutical announced that they have started clinical testing of RELISTOR (methylnaltrexone bromide) subcutaneous injection in Japan. Its the first in class medicine approved in the US, Canada, EU, Australia and Latin American countries for the treatment of opioid induced constipation.

Ono has exclusive rights to subcutaneous RELISTOR in Japan, where it is pursuing plans to develop and commercialize the drug, designated ONO-3849, for the treatment of opioid induced constipation. RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals.

ONO-3849 is being developed in Japan according to the regulatory agency guidelines of Japan’s Ministry of Health, Labor and Welfare, and will be evaluated in Japanese patients with opioid-induced constipation.